Showing 2181-2190 of 3223 results for "".
- Avellino Labs Founder Gene Lee Receives 2019 Ellis Island Medal of Honorhttps://modernod.com/news/avellino-labs-founder-gene-lee-receives-2019-ellis-island-medal-of-honor/2476683/Avellino Labs announced the company’s founder, chairman, and president, Gene Lee, is a recipient of a 2019 Ellis Island Medal of Honor. In addition, Mr. Lee has been appointed to the World Economic Forum’s Precision Medicine Council. One of the nation’s most prestigious awards, the Ellis I
- Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Deliveryhttps://modernod.com/news/alnylam-announces-progress-with-rnai-therapeutics-platform-including-oral-route-of-administration-and-cns-and-ocular-delivery/2476682/Alnylam Pharmaceuticals announced new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) – the molecules that mediate RNAi – directed to a liver target. Oral delivery could broaden the clinical
- Alcon’s iLUX MGD Treatment System Wins Top Honor in 2019 Medical Design Excellence Awards (MDEA)https://modernod.com/news/alcons-ilux-mgd-treatment-system-wins-top-honor-in-2019-medical-design-excellence-awards-mdea/2476678/Alcon was selected as a Gold winner for its personalized iLUX MGD Treatment System at the 2019 Medical Design Excellence Awards (MDEA). The award was given in the “Nonsurgical Hospital Supplies and Equipment” category during an event held on June 11 in New York City. Products w
- Alimera’s Iluvien Receives Positive NICE Recommendation for Noninfectious Posterior Uveitishttps://modernod.com/news/alimeras-iluvien-receives-positive-nice-recommendation-for-noninfectious-posterior-uveitis/2476675/Alimera Sciences announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE), in its Final Appraisal Determination for national reimbursement, has recommended funding for Iluvien 190 micrograms intravitreal implant in applicator for the prevention of relapse
- Alcon Showcases News Contact Lens Innovations and the iLUX System at the 2019 Optometry’s Meetinghttps://modernod.com/news/alcon-showcases-news-contact-lens-innovations-and-the-ilux-system-at-the-2019-optometrys-meeting/2476673/Alcon will launch Dailies Colors contact lenses at the 2019 Optometry’s Meeting, as well as give attendees a preview of PRECISION1 contact lenses coming soon to the US. These innovations, together with updates on the iLUX MGD Treatment System, new clinical data and practice insights, will be feat
- Gymnast Laurie Hernandez Partners With Alcon for New “Eye Can, Eye Will” Campaignhttps://modernod.com/news/gymnast-laurie-hernandez-partners-with-alcon-for-new-eye-can-eye-will-campaign/2476665/Alcon is teaming up with gold- and silver-medal winning gymnast Laurie Hernandez on the new “Eye Can, Eye Will” campaign, which is based on Laurie’s belief that clear, comfortable vision with DAILIES TOTAL1 contact lenses have helped her maintain the focus and enthusiasm needed to get to the top
- OcuSoft Introduces NEW OcuSoft Lid Scrub Allergy Eyelid Treatment for Red, Itchy Allergy Eyeshttps://modernod.com/news/ocusoft-introduces-new-ocusoft-lid-scrub-allergy-eyelid-treatment-for-red-itchy-allergy-eyes/2476646/OcuSoft announced the availability of new OcuSoft Lid Scrub Allergy Eyelid Cleanser for allergy conditions in convenient pre-moistened pads. OcuSoft Lid Scrub Allergy removes oil, debris, pollen and other contaminants from the eyelids while utilizing Green Tea Extract, Tea Tree Oil and PSG
- Alcon Launches Art-Focused Patient Campaign in Honor of Cataract Awareness Monthhttps://modernod.com/news/alcon-launches-art-focused-patient-campaign-in-honor-of-cataract-awareness-month/2476636/Alcon is launching a new art-focused campaign in honor of Cataract Awareness Month, which illustrates the impact cataracts can have on seeing color and encourages those diagnosed with cataracts to understand the benefits of cataract surgery. The campaign is part of Alcon’s continued co
- Allegro Ophthalmics Announces Positive Topline Results of Phase 2 Study Evaluating Risuteganib in Patients with Intermediate Dry AMDhttps://modernod.com/news/allegro-ophthalmics-announces-positive-topline-results-of-phase-2-study-evaluating-risuteganib-in-patients-with-intermediate-dry-amd/2476627/Allegro Ophthalmics announced positive topline results of its phase 2 study of risuteganib (Luminate) for the treatment of intermediate dry age-related macular degeneration (AMD). The clinical trial met its primary endpoint with 48 percent of patients in the risuteganib arm gaining ≥ 8 letters of
- Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign for Iluvienhttps://modernod.com/news/alimera-sciences-announces-launch-of-direct-to-patient-marketing-campaign-for-iluvien/2476603/Alimera Sciences announced the launch of a direct-to-patient (DTP) marketing campaign intended to raise awareness and educate patients diagnosed with diabetic macular edema (DME) and their caregivers about the therapeutic and dosing benefits of Iluvien. The campaign will be supported by the websi